SCHEMBL10243608

SCHEMBL10243608

CCN(CCNC(=O)OC)C(C)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44
ALDH1A1 P00352 2/20 0.42
ATM Q13315 1/20 0.41
HTT P42858 3/20 0.41
CYP2D6 P10635 4/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
RECQL P46063 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 2/20 0.39
CYP3A4 P08684 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243802 0.86 MGLL (0.45) KMT2AL3MBTL1MEN1ALDH1A1ATM
SCHEMBL10244077 0.83 CYP2C19 (0.42) KMT2AHPGDALDH1A1CYP2D6CYP2C9
SCHEMBL10243821 0.83 OPRK1 (0.46) LMNASLC6A3
SCHEMBL10243833 0.82 CYP2C19 (0.43) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL10243444 0.82 RAB9A (0.45) KMT2AMEN1HPGDALDH1A1HTT
SCHEMBL10243624 0.82 ACHE (0.37) HPGDALDH1A1CYP2D6CYP2C19LMNA
SCHEMBL10243851 0.82 MTNR1A (0.47)
SCHEMBL10243429 0.82 MTNR1A (0.47)
SCHEMBL10244397 0.82 MTNR1A (0.47)
SCHEMBL10243869 0.82 BCHE (0.37) ALDH1A1CYP2D6CYP2C9CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KMT2A 939/4885L3MBTL1 2853/4885MEN1 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.